A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study to Evaluate the Safety — ANTHONY O CAGGIANO (COGNITI
ABSTRACT: Cognition Therapeutics, Inc. (CogRx) is developing CT1812 for neurodegenerative conditions, including Dementia with Lewy Bodies (DLB). This first-in-class small molecule drug candidate selec
| Project title | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study to Evaluate the Safety |
|---|---|
| Project number | 5R01AG071643-03 |
| PI name | ANTHONY O CAGGIANO |
| Institution | COGNITION THERAPEUTICS, INC. |
| Funding mechanism | R01 |
| Agency | NIA |
| Award amount | $8.48M |
| Fiscal year | 2023 |
| Project start | 2021-05-15T00:00:00 |
| Project end | 2025-04-30T00:00:00 |
| Abstract | ABSTRACT: Cognition Therapeutics, Inc. (CogRx) is developing CT1812 for neurodegenerative conditions, including Dementia with Lewy Bodies (DLB). This first-in-class small molecule drug candidate selec |
| Key terms | <AD dementia><Activities of Daily Living><Activities of everyday life><Adverse Experience><Adverse e |
$799/mo
Try GrantRadar →